Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

Highlights of the American Society of Hematology Meeting 2014: Hemostaseology

ASH Meeting 2014: optimizing anticoagulation treatment

verfasst von: MD Clemens Feistritzer, MD Birgit Mosheimer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

In patients suffering from venous thromboembolism, the subsequent anticoagulation treatment significantly reduces the risk of recurrence of further thromboembolic events. However, all available treatment options put the patients at risk of potential life-threatening bleeding complications. Consequently, during the 56th Annual Meeting 2014 of the American Society of Hematology in San Francisco researchers focused on optimizing the use of the current available anticoagulants. Therefore, in the Choosing Wisely® campaign the expert committee recommended to treat patients suffering from their first venous thromboembolism in the setting of major transient risk factors for (not longer than) 3 months. In addition, a French national multicenter trial showed that—if indefinite anticoagulation is not indicated—extended treatment after spontaneous thromboembolism does not reduce the risk of recurrence after stopping the anticoagulation therapy. In patients with cancer-associated thromboembolism, a multicenter study demonstrated the superiority of low molecular heparins over vitamin K antagonist. Finally, a novel, promising target for dissecting hemostasis and antithrombotic effects might be the plasma contact system. Downregulation of factor XI levels in patients undergoing elective knee arthroplasty was an effective method for prevention of postoperative venous thrombosis without increasing the risk of bleeding.
Literatur
1.
Zurück zum Zitat Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. Blood. 2014;124:3524–8. CrossRefPubMed Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. Blood. 2014;124:3524–8. CrossRefPubMed
2.
Zurück zum Zitat Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question. Blood. 2013;122:3879–83. CrossRefPubMed Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question. Blood. 2013;122:3879–83. CrossRefPubMed
3.
Zurück zum Zitat Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52. CrossRefPubMed Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52. CrossRefPubMed
4.
Zurück zum Zitat Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. CrossRefPubMed Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. CrossRefPubMed
5.
Zurück zum Zitat Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510. CrossRefPubMed Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510. CrossRefPubMed
6.
Zurück zum Zitat Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97. CrossRefPubMed Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97. CrossRefPubMed
7.
Zurück zum Zitat Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036. PubMedCentralCrossRefPubMed Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036. PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e419S–94S. PubMedCentralCrossRefPubMed Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e419S–94S. PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558–63. CrossRefPubMed Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558–63. CrossRefPubMed
10.
Zurück zum Zitat Kyrle PA, Eischer L. Predicting the risk of recurrent venous thromboembolism. The Austrian study on recurrent venous thromboembolism (AUREC). Hamostaseologie. 2013;33:201–9. CrossRefPubMed Kyrle PA, Eischer L. Predicting the risk of recurrent venous thromboembolism. The Austrian study on recurrent venous thromboembolism (AUREC). Hamostaseologie. 2013;33:201–9. CrossRefPubMed
11.
Zurück zum Zitat Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376:2032–9. CrossRefPubMed Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376:2032–9. CrossRefPubMed
12.
Zurück zum Zitat Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–7. CrossRefPubMed Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–7. CrossRefPubMed
13.
Zurück zum Zitat Couturaud F, Sanchez O, Pernod G, et al. Two years versus six months of oral anticoagulation after a first episode of unprovoked pulmonary embolism: The Padis PE Multicenter, double-blind, randomized trial. ASH abstract #LBA-3. 2014. Couturaud F, Sanchez O, Pernod G, et al. Two years versus six months of oral anticoagulation after a first episode of unprovoked pulmonary embolism: The Padis PE Multicenter, double-blind, randomized trial. ASH abstract #LBA-3. 2014.
14.
Zurück zum Zitat Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. CrossRefPubMed Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. CrossRefPubMed
15.
Zurück zum Zitat Blot E, Gutman F, Thannberger A. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer. N Engl J Med. 2003;349:1385–87. CrossRefPubMed Blot E, Gutman F, Thannberger A. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer. N Engl J Med. 2003;349:1385–87. CrossRefPubMed
16.
Zurück zum Zitat Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;7:CD0066502014. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;7:CD0066502014.
17.
Zurück zum Zitat Lee AY, Kamphuisen PW, Meyer G, et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients—the CATCH study; ASH abstract #LBA-2. 2014. Lee AY, Kamphuisen PW, Meyer G, et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients—the CATCH study; ASH abstract #LBA-2. 2014.
18.
Zurück zum Zitat Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70. CrossRefPubMed Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70. CrossRefPubMed
19.
Zurück zum Zitat Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–204. CrossRefPubMed Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–204. CrossRefPubMed
21.
Zurück zum Zitat Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39:621–31. CrossRefPubMed Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39:621–31. CrossRefPubMed
22.
Zurück zum Zitat Maas C, Renné T. Regulatory mechanisms of the plasma contact system. Thromb Res. 2012;129 Suppl 2:S73–6. CrossRefPubMed Maas C, Renné T. Regulatory mechanisms of the plasma contact system. Thromb Res. 2012;129 Suppl 2:S73–6. CrossRefPubMed
23.
Zurück zum Zitat Gailani D. Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program. 2014(1):52–9. Gailani D. Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program. 2014(1):52–9.
24.
Zurück zum Zitat van Montfoort ML, Meijers JC. Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology Am Soc Hematol Educ Program. 2014(1):60–65. van Montfoort ML, Meijers JC. Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology Am Soc Hematol Educ Program. 2014(1):60–65.
25.
Zurück zum Zitat Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–40. CrossRefPubMed Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–40. CrossRefPubMed
Metadaten
Titel
Highlights of the American Society of Hematology Meeting 2014: Hemostaseology
ASH Meeting 2014: optimizing anticoagulation treatment
verfasst von
MD Clemens Feistritzer
MD Birgit Mosheimer
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0228-2

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe